AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study 
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training 
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio 
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement 
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares 
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling 
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026 
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector 
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands 
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift 
Hanwha Signals Readiness to Build Nuclear-Powered Submarines at Philly Shipyard for U.S. Navy 
Hyundai Recalls Over 51,000 Vehicles in the U.S. Due to Fire Risk From Trailer Wiring Issue 
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss 
GLP-1 Weight Loss Pills Set to Reshape Food and Fast-Food Industry in 2025 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio 
IRVINE, Calif., Sept. 18, 2017 -- Khang & Khang LLP (the “Firm”) announces a securities class action lawsuit against Lexmark International Inc. (“Lexmark” or the “Company”) (NYSE: LXK). Investors who purchased or otherwise acquired Lexmark shares from August 1, 2014 through July 20, 2015, inclusive (the “Class Period”), are encouraged to contact the Firm by September 19, 2017, the lead plaintiff motion deadline.
If you purchased Lexmark shares during the Class Period, please contact Joon M. Khang, Esq., of Khang & Khang LLP, 4000 Barranca Parkway, Suite 250, Irvine, CA 92604, by telephone at (949) 419-3834, or by e-mail at [email protected].
There has been no class certification in this case yet. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member as well.
The Complaint alleges that during the Class Period, Lexmark made materially false and/or misleading statements, and/or failed to disclose, that: end-user demand and growth for the Company’s supplies business was deteriorating; that pricing increases were the primary driver of supplies revenue growth, not end-user demand; that customers in the supplies channel reacted by buying ahead of anticipated pricing increases; and that as a result, there were excessive inventory levels at its European wholesale distributors. On July 21, 2015, the Company reported poor results for its second quarter ending June 30, 2015 and lowered its 2015 sales guidance. The Company revealed its supplies growth was not attributable to end-user demand but rather the result of its European customers buying ahead of customary price increases which produced excessive inventory. Following this news, Lexmark’s stock price fell materially, which caused investors harm according to the Complaint.
If you wish to learn more about this lawsuit, or if you have any questions concerning this notice or your rights, please contact Joon M. Khang, Esquire, a prominent litigator for almost two decades, by telephone at (949) 419-3834, or via e-mail at [email protected].
This press release may constitute Attorney Advertising in some jurisdictions.
Contact
Joon M. Khang, Esq.
Telephone: 949-419-3834
Facsimile: 949-225-4474
[email protected]
